Mealey's (November 13, 2017, 12:57 PM EST) -- WASHINGTON, D.C. — The owner of a patent covering the short bowel syndrome (SBS) drug Gattex argued before the Federal Circuit U.S. Court of Appeals on Nov. 9 that the Patent Trial and Appeal Board erred in deeming various claims obvious under Section 103 of the Patent Act, 35 U.S.C. § 103 (In re: NPS Pharmaceuticals Inc., No. 17-1392, Fed. Cir.)....